The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery

International Journal of Molecular Sciences

Rocco Savino¹  Sergio Paduano¹  Mariaimmacolata Preianò¹ 

[1] Department of Health Sciences, Laboratory of Mass Spectrometry and Proteomics, University “Magna Græcia”, Catanzaro, University Campus, Europa Avenue, 88100 Catanzaro, Italy;

关键词: biomarkers;    mass spectrometry;    MALDI-TOF;    proteomics;    bodily fluids;    tissues;   

DOI  :  10.3390/ijms131113926

来源: mdpi

【 摘 要 】

In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead to a disease condition. This knowledge allows the design of strategies to target multiple pathways with combinations of pathway-specific drugs, which might increase chances of success and reduce the occurrence of drug resistance. Chemical proteomics, by analyzing the drug interactome, strongly contributes to accelerate the process of new druggable targets discovery. In the research area of clinical proteomics, proteome and peptidome mass spectrometry-profiling of human bodily fluid (plasma, serum, urine and so on), as well as of tissue and of cells, represents a promising tool for novel biomarker and eventually new druggable targets discovery. In the present review we provide a survey of current strategies of functional, chemical and clinical proteomics. Major issues will be presented for proteomic technologies used for the discovery of biomarkers for early disease diagnosis and identification of new drug targets.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.